

On-line webinar: Microscale FAIMS-MS and Pharmaceutical Analysis

Date/time: Thursday 9th May, 4pm BST

Presenter: Colin Creaser
Centre for Analytical Science
Loughborough University, UK
(c.s.creaser@lboro.ac.uk)

Ion Mobility Spectrometry: Basics

- Rapid separation of gas phase ions as a result of differences in their mobility in an electric field and a buffer gas
- Two types of device:
 - Drift tube ion mobility spectrometry
 - Field asymmetric waveform ion mobility spectrometry (FAIMS) or differential mobility spectrometry (DMS)

Ion mobility spectrometry

Mobility of an ion in the presence of an electric field gradient and a buffer gas (e.g. He, N₂ or air; 1-10 mbar or 1 bar) is given by:


$$v = K \cdot E$$

[v = ion velocity, E = electric field gradient, K = ion mobility]

- This relationship only holds under low field conditions ($E \rightarrow 0$)

Ion mobility in high and low electric fields


- Mobility is dependent on electric field strength



- Alpha coefficient – compound dependent


[Purves R W, Guevremont R, Anal. Chem. 1999, 71, 2346-2357]

Field Asymmetric Waveform Ion Mobility Spectrometry (FAIMS)/Differential mobility spectrometry (DMS)




- Compensation field (CF), or voltage (CV, set to transmit ions of selected differential mobility)
- Continuous ion beam (equivalent to quadrupole mass filter)

ESI-FAIMS-MS spectrum of protonated reserpine (Owlstone miniaturised FAIMS-Agilent TOF, ESI)




Combining FAIMS with mass spectrometry: Thermo Fisher Scientific cylindrical electrode schematic

a)



(electrode gap ~ 2-3 mm)



Electrospray ion source →




→ Mass spectrometer


[Barnett et al., *J Am Soc Mass Spectrom*, 2007, 18, 1653–1663]

Prototype Owlstone miniaturised chip-based FAIMS-Agilent 6230 TOF MS: modified JetStream ESI ion source region



Miniaturised chip-based FAIMS



- Total area of chip: 4 mm²
- Electrode gap: 100 µm x 700 µm (16 electrode pairs)




Prototype Owlstone miniaturised chip-based FAIMS cartridge located behind spray shield of the Jet Stream ESI source of an Agilent 6230 TOF MS



<http://prezi.com/uqsyffbbdsmf/introduction-to-owlstone-ultrafaims/>


FAIMS combined with mass spectrometry: orthogonal separation enhances analytical space




Applications of FAIMS-MS

- Isobaric and isomeric compounds

ESI-FAIMS-MS of 2,4,6-trimethylaniline and N,N-dimethyl-*m*-toluidine
(Dispersion field = 230 Td; electrode gap = 100 µm; 50 ng/ml)





ESI-FAIMS-MS of isomeric o- and m-phthalic acids
(Dispersion field = 200 Td; electrode gap = 100 μ m) – 0.5% 2-Butanol




Applications of FAIMS-MS

- Reducing sample complexity/chemical noise

ESI-FAIMS-TOFMS analysis of PEG/HOPB mixture





Protonated PEG (m/z 327.2013)




HOBP (m/z 327.1955)

ESI-FAIMS-TOFMS analysis of PEG/HOPB mixture



U(H)PLC-FAIMS-TOFMS analysis (-ve ion) of (R/S) ibuprofen 1- β -O acyl glucuronide (IAG) in human urine



U(H)PLC-FAIMS-TOFMS analysis (-ve ion) of (R/S) ibuprofen 1- β -O acyl glucuronide (IAG) in human urine

Comparison of LOQ; LDR (R^2) and intra-day reproducibility for the determination of IAG spiked into urine (15.5 μ g/ml, n=5)


| | LC-MS | LC-FAIMS-MS |
|-------------------|----------|-------------|
| LOQ (μ g/ml) | 0.018 | 0.010 |
| LDR (μ g/ml) | 0.018-11 | 0.010-11 |
| R^2 | 0.9991 | 0.9987 |
| Intra-day (% RSD) | 5.0 | 2.7 |

[Smith et al, *J. Chromatogr. A*, 127, 76-81, 2013]

Applications of FAIMS-MS


- Charge state and conformers

Bradykinin nano-ESI-LTQ mass spectrum without FAIMS separation
(DV 60 kV cm⁻¹; 22 MHz; N₂ drift gas; CV scan 0.5 V cm⁻¹; 10 pmol µl⁻¹)




[L Brown et al., *Anal. Chem.*, 2010, 82, 9827-9834]

Bradykinin NSI-FAIMS-LTQ mass spectrum with FAIMS pre-selection of $[M+2H]^{2+}$ ion (CV 3.5-3.6 V)



[L Brown et al., *Anal. Chem.*, 2010, 82, 9827; *Current Analytical Chemistry*, 9, 192, 2013]

MS and FAIMS-MS of Ubiquitin




(a) Mass spectrum of Ubiquitin, (b) FAIMS spectrum of $[M+6H]^{6+}$ (m/z 1428), (c) FAIMS spectrum of $[M+13H]^{13+}$ (m/z 659) [FAIMS DF = 60 kV/cm]

Applications of FAIMS-MS

- Enhancing FAIMS-MS selectivity


FAIMS-selected in-source CID-MS (FISCID-MS)




[Brown, L; Smith, R et al., *Anal Chem*, 2012, 84, 4095]

ESI-FAIMS-TOFMS analysis of PEG/HOBP mixture

No FAIMS



FAIMS-selected HOBP




Protonated PEG (m/z 327.2013) and HOBP (m/z 327.1955) ions

[Brown, L; Smith, R et al., *Anal Chem*, 84, 4095, 2012]


ESI-FISCID-TOFMS analysis of PEG/HOPB mixture

FAIMS-in source CID-MS: CV = 0.6 - 0.7V




MS of peptide mixture without FAIMS separation

- Owlstone FAIMS-Agilent TOF MS: no FAIMS selection




FAIMS-MS of peptide mixture with FAIMS pre-selection of Bradykinin (m/z 531, $[M+2H]^{2+}$)

- Owlstone FAIMS-Agilent TOF MS: CV = 2.6-2.7 selected



FISCID-MS of peptide mixture with FAIMS pre-selection of Bradykinin (m/z 531, $[M+2H]^{2+}$) and in-source CID

➤ Owlstone FAIMS-Agilent TOF MS; CV = 2.6-2.7; Fragmentor 350 V



FAIMS-mass spectrometry: Conclusions

- FAIMS-MS configurations allow orthogonal separation of ions based on differential ion mobility and m/z (and retention time with LC or GC)
 - Enhanced analytical space (improved peak capacity)
- Separation of isobaric/isomeric ions (in some cases)
- Charge state/conformer separation
- Reduction in sample complexity:
 - Improved S:N and discrimination of target ions from background chemical noise
 - Enhanced quantitative performance
- Wide range of structural, qualitative and quantitative applications

Further reading and FAIMS publications

Creaser group miniaturised FAIMS publications:

- R. W. Smith, D. E. Toutoungi, J C Reynolds, A. W.T. Bristow, A. Ray, A. Sage, I. D. Wilson, D. J. Weston, B. Boyle, C. S. Creaser, *J. Chromatogr. A*, 2013, 127, 76.
- L. J. Brown, C. S. Creaser, *Curr. Anal. Chem.*, 2013, 9, 192.
- L. J. Brown, R. W. Smith, D. E. Toutoungi, J C Reynolds, A. W.T. Bristow, A. Ray, A. Sage, I. D. Wilson, D. J. Weston, B. Boyle, C. S. Creaser, *Anal Chem*, 2012, 84, 4095.
- L. J. Brown, D. E. Toutoungi, N. A. Devenport, J. C. Reynolds, G. Kaur-Atwal, B. Boyle, C. S. Creaser, *Anal. Chem.*, 2010, 82, 9827.

Further reading:

- R. Guevremont, High-field asymmetric waveform ion mobility spectrometry: a new tool for mass spectrometry, *J Chromatogr A*, 2004, 1058, 3.
- B. M. Kolakowski, Z. Mester, Review of applications of high-field asymmetric waveform ion mobility spectrometry and differential mobility spectrometry. *Analyst*, 2007, 132, 842.
- A. A. Shvartsburg, Differential ion mobility spectrometry: nonlinear ion transport and fundamentals of FAIMS, CRC Press, Boca Raton, 2009.

Acknowledgements

Loughborough: Caitlyn Da Costa, Neil Devenport, Alex Hill, Aditya Malkar, Rob Smith, Vicky Wright, Dr Jim Reynolds, Dr Steve Christie, Prof Paul Thomas

AstraZeneca: Tony Bristow, Andy Poulton, Andy Ray, Dan Weston, Ian Wilson (Imperial)

Owlstone Limited: Danielle Toutoungi, Billy Boyle, Lauren Brown

Agilent Technologies: Michael Ugarov, George Stafford, Ashley Sage (Sciex)

Funding:

BBSRC, EPSRC, Agilent Technologies, AstraZeneca, Castrol, LGC,
Loughborough University, Owlstone